Temsavir, also known as BMS-626529, is primarily used in the treatment of HIV-1 infection. It functions as an attachment inhibitor, specifically targeting the gp120 protein on the surface of the HIV virus. By binding to gp120, Temsavir prevents the virus from attaching to and entering human CD4+ T cells, a critical step in the viral replication cycle. This drug is particularly beneficial for patients who have developed resistance to other antiretroviral therapies. It is often administered in combination with other antiretroviral agents to enhance its efficacy and reduce the risk of further resistance development. Temsavir is typically prescribed for adults who have limited treatment options due to multidrug-resistant HIV-1 strains. The application of Temsavir represents a significant advancement in HIV treatment, offering a new mechanism of action that complements existing therapies. Its use helps to improve viral load suppression and immune system recovery in patients who have struggled to achieve these outcomes with other medications.